You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Avalon said that as part of the agreement it is working with Cellex to source manufacturing facilities and develop next-generation COVID-19 testing kits.
The firm said its genetic tests for breast, prostate, and colorectal cancers and melanoma assess a patient's personal cancer risks and guide personalized prevention.
Under the agreement, Unilabs will help test airline passengers flying into UAE to determine if they are infected with the virus.
The test is designed to detect the ORF1ab and nucleocapsid genes of the virus in upper respiratory specimens such as nasal swabs or nasal aspirates.
For the three months ended July 31,the firm's revenues contracted to $1.26 billion from $1.27 billion in Q3 2019, beating Wall Street analysts' average estimate of $1.21 billion.
The chemiluminescent test targets antibodies against the virus' S1 protein which the firm believes is a particularly clinically relevant marker.
The firm can now tell customers if their genotypes may impact their response to clopidogrel and citalopram without the need for confirmatory testing.
The announcement follows widespread concern just weeks ago that laboratories across the country were struggling with their testing capacity.
Saying pooled testing for coronavirus was not for diagnostic purposes, Cigna had said it wouldn't reimburse for the method, but it plans to change its policy.
The company received Emergency Use Authorization from the US Food and Drug Administration for another SARS-CoV-2 antibody test early last month.
Quidel sued Siemens Healthineers claiming false advertising associated with a competing assay that measures thyroid-stimulating immunoglobins to detect Graves' disease.
A letter to users regards inaccurate results due to inadequate sample processing and an issue with interpretive software.
The organization had previously only recommended the use of noninvasive prenatal testing in individuals 35 and older or with other known risk factors.
The California-based genetic testing firm said its new lab will be able to process 20,000 tests per day and will initially focus on COVID-19 testing.
The report noted that savings from the lower payment rates were offset by increased spending on other tests, including genetic tests.
The companies said they will collaborate on driving operational improvements, creating price transparency, and improving consumer engagement and outcomes.
The deal gives Fujifilm global distribution rights to Inspirata's Dynamyx digital pathology workflow software with exclusivity in certain European markets.
The test could be used in most high-complexity labs because it has been authorized for use with different combinations of frequently used reagents and instruments.
OneOncology, a network comprising community oncology practices across the US, will bring its patient data to the research-focused partnership.
Under the terms of the agreement Thermo Fisher will retain the rights to commercialize the companion test globally and seek regulatory approval.
The Pro-Lab Diagnostic Pro-AmpRT SARS-CoV-2 test consists of six primers and amplifies a 206 base-pair region of the ORF1ab gene of SARS-CoV-2.
The commercial labs will also receive testing equipment from Beckman Coulter Life Sciences and Thermo Fisher Scientific including RT-PCR instrumentation.
The firm reported total revenues of $93.2 million, down from $215.4 million in fiscal Q4 2019 and short of the consensus Wall Street estimate of $93.9 million.
During the second quarter, the company performed 75,017 tests for noninvasive prenatal testing, carrier screening, and SARS-CoV-2.
News items for the in vitro diagnostics industry for the week of August 10, 2020.